Improve GMP management level

Improve GMP management level and expand European market

Wuxi Jida Pharmaceutical Co., Ltd. was founded in June 2005, and has been developing since -- Zhizhi We are committed to the research, development and production of high-end APIs that meet the Chinese Pharmacopoeia, US USP and European EP standards. For a long time, with the development concept of "integrating science and technology into life and turning quality into health",The company's three quality policies: strive to improve product quality, strive to achieve zero defects in product quality Zero complaints; Adhere to the use of advanced technologies, processes and systems to ensure quality control throughout the production process System; Establish a highly motivated professional quality management team to stabilize and improve the quality of the enterprise System.Since the establishment of the company, many varieties have passed the GMP inspection of the National Bureau and overseas markets such as North America The products are sold to overseas markets except Europe. In 2011, according to the company's development Plan to comprehensively improve the quality of citalopram hydrobromide, the main product,

On October 2, 2012, citalopram hydrobromide successfully passed the European Drug Administration (EDQM) And obtained the COS certificate (No. RO-CEP 2011-214-Rev00). The company is implementing Eu GMP and 2010 GMP levels in China have been greatly improved again, with antidepressant analogues The acquisition of the COS certificate of citalopram hydrobromide enables the product to be sold to the European regular market It has broad prospects. The following figure shows the COS Certificate of Citalopram Hydrobromide